Categories AlphaGraphs, Earnings, LATEST, Technology
Facebook misses on topline in Q2; stock crashes 9%
Facebook’s shares tumbled 9% Wednesday after it reported second-quarter revenue that missed street expectations. Revenue grew 42% to $13.23 billion but came below average analysts’ expectation of $13.36 billion after being embroiled in a slew of data leaks and fake news scandals.
Meanwhile, earnings came in at $1.74 per share, topping consensus estimate $1.72 a share. Last year same quarter, Facebook had posted profits of $1.32 a share, on revenue of $9.32 billion.
LIVE BLOG: Facebook Q2 2018 earnings call
In the second quarter, ad revenue, the largest revenue contributor for the company, jumped 42% to $13 billion. Analysts had projected ad revenue growth of about 40% – 50%. Meanwhile, mobile advertising revenue represented about 91% of the total advertising revenue.
Facebook also managed to boost its average revenue per user, which grew from $23.59 during Q1 to $25.91 in the US & Canada.
RELATED: Facebook Q2 2018 earnings call transcript
The #deletefacebook movement and Cambridge Analytica scandal slowed Facebook’s user base growth further in Q2 (See IG below). During the quarter, the company reported 11% increase in its daily active users. There were around 2.23 billion monthly active users as of June 30, 2018, up 11% compared to last year.
Related: Earnings preview: Embattled Facebook expected to maintain momentum in Q2
Over the last three years, shares of Facebook have surged roughly 120% and on Tuesday, the company’s stock had hit a record high.
Related Infographic
Most Popular
United Parcel Service (UPS) seems on track to regain lost strength
Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic
IPO Alert: What to look for when Boundless Bio goes public
Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.
Nike (NKE) bets on innovation and partnerships to return to high growth
Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company